Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Salix Pharmaceuticals, Ltd. 

1700 Perimeter Park Drive

Morrisville  North Carolina  27560  U.S.A.
Phone: 919-862-1000 Fax: 919-862-1095



 Company News
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce Initiation Of Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 8/28/2014 10:58:01 AM
Allergan Inc. (AGN) Approaches Salix Pharmaceuticals, Ltd. (SLXP) To Fend Off Valeant Pharmaceuticals International (VRX)'s Hostile Bid 8/20/2014 6:27:57 AM
Salix Pharmaceuticals, Ltd. (SLXP) Announces Early Termination Of HSR Waiting Period For Pending Transaction 8/19/2014 10:15:22 AM
Salix Pharmaceuticals, Ltd. (SLXP) Announces Important Topline Results For Microbiome, Culture & Susceptibility, And Key Secondary Efficacy Results For TARGET 3, Rifaximin IBS-D Repeat Treatment Study 8/12/2014 8:53:48 AM
Salix Pharmaceuticals, Ltd. (SLXP) Release: FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date For RELISTOR® Subcutaneous Injection Snda For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-Cancer Pain 8/11/2014 8:24:49 AM
Salix Pharmaceuticals, Ltd. (SLXP) Announces 2Q2014 Financial Results Conference Call And Webcast 7/24/2014 12:56:43 PM
Pharming Group (PHGUF.PK), Salix Pharmaceuticals, Ltd. (SLXP) Wins FDA Approval For Ruconest® 7/17/2014 8:27:12 AM
FDA Office Of Drug Evaluation III Approves Salix Pharmaceuticals, Ltd. (SLXP)’s Request That The FDA Approve The RELISTOR® Subcutaneous Injection sNDA For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-Cancer Pain 7/14/2014 11:32:00 AM
Salix Pharmaceuticals, Ltd. (SLXP) Scoops Up Cosmo Technologies For Tax Savings 7/9/2014 8:41:55 AM
Salix Pharmaceuticals, Ltd. (SLXP) Surges On Encouraging Phase 3 Results For Rifaximin; Stock Up +13.51% At Market Close (July 1, 2014) 7/1/2014 8:10:23 AM